美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

百濟神州

337.89

+17.525.47%

盤後：337.890.00000.00%19:11 EST

成交量：66.66萬

成交額：2.24億

市值：402.09億

市盈率：577.88

高：340.81

開：329.29

低：328.75

收：320.37

52周最高：385.22

52周最低：174.74

股本：1.19億

流通股本：7,564.19萬

量比：1.89

換手率：0.88%

股息：- -

股息率：- -

每股收益(TTM):0.5847

每股收益(LYR):-6.1240

淨資產收益率：1.81%

總資產收益率：1.69%

市淨率：9.74

市盈率(LYR):-55.17

資料載入中...

總覽公司新聞資訊公告

醫保商保「雙目錄」出爐！5款百萬一針抗癌藥CAR-T獲納入，司美格魯肽、替爾泊肽在列

「百萬一針」抗癌藥、阿爾茲海默等用藥在列！醫保商保「雙目錄」重磅出爐

百濟神州兩款藥品進入2025年商保創新藥目錄

百濟神州(06160)授出合共2.13萬個受限制股份單位

疫情紅利過去，全球醫藥企業大洗牌，投資的確定性機會在哪？

醫藥生物行業2026年度策略報告：多元支付啓新程，掘金廣闊藍海

醫療器械及醫療服務2026年展望：行業持續復甦長線佈局機會顯現

中信建投证券

近一個月內，我武生物等多家國內藥企研發項目終止！

科創生物醫藥ETF漲1.42%，成交額737.09萬元

本月醫藥企業成機構調研熱門板塊，百濟神州表現尤為突出！

趨勢研判！2025年中國BTK抑制劑行業發展歷程、產業鏈、市場規模、競爭格局及發展趨勢分析：市場呈現出巨大增長潛力，未來市場競爭愈加激烈[圖]

創新藥10年冰火淬鍊：千億BD交易背後的繁榮和挑戰（上）丨2025·大覆盤

醫藥生物行業跟蹤周報：藥店現金流穩健、估值低，重點推薦益豐藥房、大參林等【東吳醫藥朱國廣團隊】

国广有话说

百濟神州早盤高開逾3% 中信建投維持「買入」評級

港股異動 | 百濟神州(06160)高開逾3% 百赫安聯合百澤安與化療的3期臨牀研究取得積極結果

百濟神州授出1.65萬股受限制股份單位激勵員工

險資四季度掃貨高股息，百濟神州、匯川技術成調研「新寵」

百濟神州(06160)：授出合共1.65萬股美國存托股份受限制股份單位

11月以來機構調研聚焦成長與防禦方向

大众证券报

信達生物高管錢鐳：百濟神州是窗口期的產物

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":337.89,"timestamp":1767992400000,"preClose":320.37,"halted":0,"volume":666560,"hourTrading":{"tag":"盘后","latestPrice":337.89,"preClose":337.89,"latestTime":"19:11 EST","volume":1741,"amount":588266.48,"timestamp":1768003880090},"delay":0,"floatShares":75641900,"shares":119000000,"eps":0.584711,"marketStatus":"休市中","change":17.52,"latestTime":"01-09 16:00:00 EST","open":329.29,"high":340.81,"low":328.745,"amount":224442778.449807,"amplitude":0.03766,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.584711,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":320.37,"preHourTrading":{"tag":"盘前","latestPrice":329.2,"preClose":320.37,"latestTime":"09:25 EST","volume":17713,"amount":5678005.77105,"timestamp":1767968700004},"postHourTrading":{"tag":"盘后","latestPrice":337.89,"preClose":337.89,"latestTime":"19:11 EST","volume":1741,"amount":588266.48,"timestamp":1768003880090},"volumeRatio":1.887329519775136,"impliedVol":0.3822,"impliedVolPercentile":0.0279},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75641900,"roa":"1.69%","roe":"1.81%","lyrEps":-6.124009,"volumeRatio":1.887329519775136,"shares":119000000,"dividePrice":0,"high":340.81,"amplitude":0.03766,"preClose":320.37,"low":328.745,"week52Low":174.74,"pbRate":"9.74","psRate":"8.09","week52High":385.22,"institutionHeld":0,"latestPrice":337.89,"eps":0.584711,"divideRate":0,"volume":666560,"delay":0,"ttmEps":0.584711,"open":329.29,"prevYearClose":303.81,"prevWeekClose":311.02,"prevMonthClose":303.81,"prevQuarterClose":303.81,"fiveDayClose":311.02,"twentyDayClose":322.68,"sixtyDayClose":320.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"ONC","fiscalQuarterEnding":"2025/09","expectedEps":0.72,"name":null,"time":"盤後","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":1.09},{"date":"2025-08-30","symbol":"ONC","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756540800000,"name":null,"time":"盤前","dateTimestamp":1756526400000,"actualEps":null},{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2917,"buy":0.6667,"hold":0,"sell":0.0417,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":24,"updateTime":1764046800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2026-01-09","current":577.875224,"percent":0.94335,"low":-217.585346,"twenty":-87.22937,"median":-40.570085,"eighty":-21.930759,"high":609.337035,"avg":-8.611365,"sd":193.0466,"marketCap":35451485198},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-13","current":-89.808695,"twenty":-44.177303,"median":-38.271158,"eighty":-22.941372,"marketCap":35237878321},{"date":"2025-06-20","current":-76.439732,"twenty":-44.40516,"median":-38.484462,"eighty":-23.038971,"marketCap":29992352055},{"date":"2025-06-27","current":-76.95683,"twenty":-44.800569,"median":-38.641761,"eighty":-23.063278,"marketCap":30195243589},{"date":"2025-07-03","current":-74.11053,"twenty":-45.138397,"median":-38.836841,"eighty":-23.158686,"marketCap":29078452032},{"date":"2025-07-11","current":-76.495446,"twenty":-45.905367,"median":-39.006759,"eighty":-23.171606,"marketCap":30014212230},{"date":"2025-07-18","current":-87.653233,"twenty":-47.435675,"median":-39.313748,"eighty":-23.176246,"marketCap":34392148550},{"date":"2025-07-25","current":-89.648478,"twenty":-48.541013,"median":-39.640999,"eighty":-23.189441,"marketCap":35175014575},{"date":"2025-08-01","current":-91.060669,"twenty":-60.626235,"median":-39.865155,"eighty":-23.250607,"marketCap":35729110635},{"date":"2025-08-08","current":-184.757225,"twenty":-63.824658,"median":-40.051934,"eighty":-23.50984,"marketCap":32820458238},{"date":"2025-08-15","current":-191.818248,"twenty":-64.911375,"median":-40.112152,"eighty":-23.522344,"marketCap":34074785315},{"date":"2025-08-22","current":-194.469228,"twenty":-72.041871,"median":-40.222554,"eighty":-23.535152,"marketCap":34545708113},{"date":"2025-08-29","current":-184.552827,"twenty":-72.8475,"median":-40.343171,"eighty":-23.581122,"marketCap":32784148770},{"date":"2025-09-05","current":-197.417514,"twenty":-73.864189,"median":-40.425269,"eighty":-23.723244,"marketCap":35069444682},{"date":"2025-09-12","current":-208.147892,"twenty":-74.224679,"median":-40.801852,"eighty":-23.82061,"marketCap":36975599617},{"date":"2025-09-19","current":-212.503459,"twenty":-75.66857,"median":-40.932054,"eighty":-23.865007,"marketCap":37749326897},{"date":"2025-09-26","current":-203.715512,"twenty":-76.587723,"median":-41.008162,"eighty":-23.928977,"marketCap":36188227257},{"date":"2025-10-03","current":-213.916471,"twenty":-77.910534,"median":-41.112345,"eighty":-23.950329,"marketCap":38000335866},{"date":"2025-10-10","current":-208.109485,"twenty":-81.639564,"median":-41.598105,"eighty":-24.044918,"marketCap":36968777077},{"date":"2025-10-17","current":-197.090466,"twenty":-85.2662,"median":-41.668284,"eighty":-24.084563,"marketCap":35011347487},{"date":"2025-10-24","current":-192.138725,"twenty":-87.584871,"median":-41.753651,"eighty":-24.09529,"marketCap":34131715179},{"date":"2025-10-31","current":-191.016991,"twenty":-89.061223,"median":-41.811067,"eighty":-24.120226,"marketCap":33932449287},{"date":"2025-11-07","current":-207.03708,"twenty":-89.680521,"median":-41.96845,"eighty":-24.175905,"marketCap":36778273935},{"date":"2025-11-14","current":594.631071,"twenty":-89.43801,"median":-41.811067,"eighty":-24.044918,"marketCap":40761959883},{"date":"2025-11-21","current":563.847015,"twenty":-89.201535,"median":-41.753651,"eighty":-23.82061,"marketCap":38651712910},{"date":"2025-11-28","current":549.835185,"twenty":-89.104768,"median":-41.685343,"eighty":-23.530029,"marketCap":37691201965},{"date":"2025-12-05","current":534.967794,"twenty":-89.063642,"median":-41.61723,"eighty":-23.184163,"marketCap":36672042310},{"date":"2025-12-12","current":517.921144,"twenty":-88.590694,"median":-41.129457,"eighty":-23.039198,"marketCap":35503494432},{"date":"2025-12-19","current":495.611986,"twenty":-88.19516,"median":-41.047814,"eighty":-22.787779,"marketCap":33974201659},{"date":"2025-12-26","current":503.21518,"twenty":-87.945005,"median":-40.950457,"eighty":-22.473183,"marketCap":34495400571},{"date":"2026-01-02","current":490.430192,"twenty":-87.636143,"median":-40.899758,"eighty":-22.105685,"marketCap":33618989662},{"date":"2026-01-09","current":517.162439,"twenty":-87.22937,"median":-40.570085,"eighty":-21.930759,"marketCap":35451485198}],"updateTime":1768086788717},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589587246","title":"醫保商保「雙目錄」出爐！5款百萬一針抗癌藥CAR-T獲納入，司美格魯肽、替爾泊肽在列","url":"https://stock-news.laohu8.com/highlight/detail?id=2589587246","media":"红星新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589587246?lang=zh_tw&edition=fundamental","pubTime":"2025-12-07 20:07","pubTimestamp":1765109220,"startTime":"0","endTime":"0","summary":"今年9月，5款高价抗癌药CAR-T均通过了商保创新药目录专家评审，此后CAR-T能否纳入商保就一直备受关注。资料显示，CAR-T是嵌合抗原受体T细胞免疫疗法的简称，主要用于白血病、淋巴瘤和多发性骨髓瘤。由于“一人一药”的定制属性，CAR-T定价普遍高达百万元一针，由于价格高昂，此前始终未能踏进国家医保谈判“门槛”。至此，达伯舒目前获批的八项适应症已全部进入医保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207200750a728fe74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207200750a728fe74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LLY","IE00BZ1G4Q59.USD","06160","BK4022","688235","BK4230","BK4532","BK4585","BK4599","LU1093756325.SGD","02126","09926","IE00BKVL7J92.USD","BK4588","LU1093756168.USD","02591","LU0154236417.USD","02171","ONC","NVO","BK4007"],"gpt_icon":1},{"id":"2589879327","title":"「百萬一針」抗癌藥、阿爾茲海默等用藥在列！醫保商保「雙目錄」重磅出爐","url":"https://stock-news.laohu8.com/highlight/detail?id=2589879327","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589879327?lang=zh_tw&edition=fundamental","pubTime":"2025-12-07 15:51","pubTimestamp":1765093912,"startTime":"0","endTime":"0","summary":"12月7日上午，2025年国家医保药品目录及首版商保创新药目录在广州发布。2025年国家医保药品目录成功新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。本次目录调整同时调出了29种临床没有供应或可被其他药物更好替代的药品，其中9种尚有相同治疗主成分的其他剂型在目录内，不减少目录编号。与此同时，19种药品纳入首版商保创新药目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584579758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","IE00BJJMRY28.SGD","LU2106854487.HKD","LU1064131342.USD","LU0320765059.SGD","LU0079474960.USD","LU1712237335.SGD","BK4007","BK4588","LU1093756325.SGD","LU0882574139.USD","LU2456880835.USD","LU0471298694.HKD","LU0708995401.HKD","LU1057294990.SGD","LU1548497426.USD","SG9999018865.SGD","IE0009355771.USD","LU1571399168.USD","LU2023250504.SGD","LU2471134879.HKD","SGXZ51526630.SGD","BK0188","BK0012","LU2471134952.CNY","LU2265009873.SGD","LU0256863902.USD","LU2089984988.USD","LU2264538146.SGD","LU1061106388.HKD","LU2063271972.USD","LU2468319806.SGD","IE00BN29S564.USD","LU0267386448.USD","LU0823416689.USD","LU1988902786.USD","IE00BK4W5M84.HKD","LU1023059063.AUD","LU2168564149.EUR","BK0187","SG9999014898.SGD","LU2746668461.USD","IE00B1BXHZ80.USD","LU1232071149.USD","LU0289739699.SGD","LU2361044865.SGD","LU2087625088.SGD","BK1161","LU2237443382.USD","LU2552382215.SGD","LU2108987350.USD","LU1366192091.USD","BK1587","LU2361044949.HKD","SG9999014914.USD","LU0096364046.USD","LU1430594728.SGD","SG9999015945.SGD","BK0028","LU2237443465.HKD","BK4532","BMY","LU2360032135.SGD","LU2746668974.SGD","TAK","LU1127390331.HKD","LU2491050071.SGD","06160","IE00BJT1NW94.SGD","LU0786609619.USD","IE00BKDWB100.SGD","LU2237438978.USD","LU1093756168.USD","SGXZ81514606.USD","IE00BJLML261.HKD","LU0985481810.HKD","SG9999018857.SGD","LU0385154629.USD","LU1868836914.USD","SG9999015952.SGD","LU2211815571.USD","LU0203202063.USD","BK1585","BK1583","LU0109394709.USD","LU1868836757.USD","LU0353189763.USD","SG9999001176.USD","GB00BDT5M118.USD","LU0417517546.SGD","LU1267930730.SGD","LU2324357040.USD","LU0114720955.EUR","LU2417539215.USD","LU2461242641.AUD","LU1670711040.USD","LU1720051108.HKD","LU2125154935.USD","BK0239","LU0456855351.SGD","LU1623119135.USD","LU2236285917.USD","LU0432979614.USD","LU2125154778.USD","LU0320765992.SGD","IE00BWXC8680.SGD","LU0820561818.USD","IE00B2B36J28.USD","LU0823434583.USD","LU1868837300.USD","LU0323591593.USD","LU1551013342.USD","BK4533","LU0471298777.SGD","LU0640476718.USD","LU2357305700.SGD","SG9999017495.SGD","BK1574","LU1032466523.USD","LU2168564495.EUR","LU2237443549.SGD","LU2361045086.USD","LU0321505439.SGD","LU1670711123.USD","IE0005OL40V9.USD","LU0672654240.SGD","LU0466842654.USD","02171","LU0820561909.HKD","LU2133065610.SGD","IE00B1XK9C88.USD","LU0354030511.USD","IE00BFTCPJ56.SGD","LU1323610961.USD","LU0943347566.SGD","LU1983299246.USD","IE0004445015.USD","LU2360106947.USD","BK4581","LU0882574055.USD","LU2552382058.USD","LU1291159041.SGD","LU0225771236.USD","SG9999001176.SGD","SG9999013999.USD","IE00B7KXQ091.USD","LU0238689110.USD","LU0689472784.USD","SGXZ57979304.SGD","LU1261432733.SGD","01228","LU1035775433.USD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU0256863811.USD","LU0058720904.USD","LU1069344957.HKD","BK4585","LU2471134523.USD","BK0096","LU0122379950.USD","LU0198837287.USD","LU1280957306.USD","IE0004445239.USD","LU2552382132.HKD","LU2750360997.AUD","LU0306806265.USD","LU1551013425.SGD","IE00BK4W5L77.USD","LU0354030438.USD","BK0196","LU0106261372.USD","LU2491050154.USD","ONC","LU2242646821.SGD","SGXZ31699556.SGD","LU1670710588.SGD","LU1868836591.USD","IE00BKPKM429.USD","BK4559","LU1974910355.USD","LU2112291526.USD","LU0353189680.USD","LU0225284248.USD","IE00BFXG1179.USD","LU0316494557.USD","BK0183","LU2462157665.USD","LU2471134796.USD","SG9999014880.SGD","02126","IE0002141913.USD","LU0234572021.USD","LU2237443978.SGD","688235","SG9999015978.USD","LU0306807586.USD","LU2168564222.USD","BK4599","LU1917777945.USD","LU1868837136.USD","SG9999015986.USD","BK4516","IE00B4JS1V06.HKD","LU2242652126.USD","SG9999014906.USD","LU2168563687.JPY","LU0061475181.USD","LU2168564065.EUR","LU1074936037.SGD","LU1814569148.SGD","LU1585245621.USD","LU0889565916.HKD","LU2237443895.HKD","600196","BK4534","LU1720051017.SGD","IE00BJJMRX11.SGD","LU0266013472.USD","02196","LU2491049909.HKD","LU0203201768.USD","LU0006306889.USD","BK0175","IE00BFSS8Q28.SGD","IE00B775H168.HKD","LU1804176565.USD","LU1670710661.SGD","LU1718418525.SGD","LU1989771016.USD","SGXZ99366536.SGD","LU0094547139.USD","LU2602419157.SGD","LU0097036916.USD","LU0823434740.USD","IE00BFSS7M15.SGD","LU2750360641.GBP","IE00B4R5TH58.HKD","LU2237443622.USD","LU0109391861.USD","LU0868494617.USD","LU0321505868.SGD","IE00BSNM7G36.USD"],"gpt_icon":1},{"id":"2589387525","title":"百濟神州兩款藥品進入2025年商保創新藥目錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2589387525","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589387525?lang=zh_tw&edition=fundamental","pubTime":"2025-12-07 13:56","pubTimestamp":1765086982,"startTime":"0","endTime":"0","summary":"【百济神州两款药品进入2025年商保创新药目录】12月7日，《商业健康保险创新药品目录（2025年）》正式发布，18家创新药企业的19款药品成功纳入，其中，百济神州有两款药品成功纳入，包括达妥昔单抗β注射液以及注射用泽尼达妥单抗。百济神州也是唯一一家两款产品进入商保创新药目录的创新药企。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512073584561139.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512073584561139.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4526","688235","BK4139","LU1969619763.USD","BK1161","ONC","LU0588546209.SGD","06160","LU1770034418.SGD","LU0307460666.USD","LU1303224171.USD","BK1500","BK1583","BK4585","LU1719994722.HKD","159992","BK1574","LU2328871848.SGD","06978","BK0239","BK1588","LU1251922891.USD"],"gpt_icon":0},{"id":"2588002521","title":"百濟神州(06160)授出合共2.13萬個受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2588002521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588002521?lang=zh_tw&edition=fundamental","pubTime":"2025-12-04 16:53","pubTimestamp":1764838411,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年11月28日，董事会薪酬委员会根据2016期权及激励计划的条款授予147名承授人合共2.13万股美国存托股份受限制股份单位。该等受限制股份单位相当于27.66万股股份，约占本公告之日公司发行股份总数的0.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","LU0307460666.USD","LU1719994722.HKD","BK0239","LU1303224171.USD","LU2328871848.SGD","688235","06160","BK4139","BK1500","BK4526","LU1770034418.SGD","BK4585","BK1161","LU0588546209.SGD","LU1251922891.USD","BK1583","LU1969619763.USD","BK1588"],"gpt_icon":0},{"id":"2587792067","title":"疫情紅利過去，全球醫藥企業大洗牌，投資的確定性機會在哪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2587792067","media":"桓睿天泽","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587792067?lang=zh_tw&edition=fundamental","pubTime":"2025-11-30 20:41","pubTimestamp":1764506493,"startTime":"0","endTime":"0","summary":"新冠疫情期间，疫情相关产品的爆发式需求曾短暂重塑头部阵营。2025年来，礼来依靠替尔泊肽在肥胖和糖尿病领域的统治性表现，市值飙升至超1万亿美元，直接登顶全球药企第一，也成为全球唯一的超万亿级的医药企业。医药行业的共性在于周期长、投入大、不确定性高。医药行业的进展并不是一条直线，而是由一个个关键节点决定的。这样做，才有可能真正抓住“中国有望诞生全球最大医药公司”这一历史性机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251130204721a4c3b528&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251130204721a4c3b528&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","BK4526","ONC","BK4139","BK4585"],"gpt_icon":0},{"id":"2587792066","title":"醫藥生物行業2026年度策略報告：多元支付啓新程，掘金廣闊藍海","url":"https://stock-news.laohu8.com/highlight/detail?id=2587792066","media":"上海证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587792066?lang=zh_tw&edition=fundamental","pubTime":"2025-11-30 18:06","pubTimestamp":1764497190,"startTime":"0","endTime":"0","summary":"风险提示：行业政策变动风险；药品/耗材降价风险；研发风险；国际化风险；市场竞争加剧风险等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251130180633a71aa1ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251130180633a71aa1ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","01530","BK4139","ONC","BK4526"],"gpt_icon":0},{"id":"2587792099","title":"醫療器械及醫療服務2026年展望：行業持續復甦 長線佈局機會顯現","url":"https://stock-news.laohu8.com/highlight/detail?id=2587792099","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587792099?lang=zh_tw&edition=fundamental","pubTime":"2025-11-30 00:00","pubTimestamp":1764432000,"startTime":"0","endTime":"0","summary":"核心观点：随着医疗器械相关政策缓和、集采出清、新产品新业务拓展和出海布局，预计26年多家医疗器械龙头公司迎来业绩拐点，建议把握业绩估值修复投资机会，以及脑机接口、AI医疗等医疗新科技方向投资机会；近期迈瑞医疗、新产业、惠泰医疗等部分大市值龙头公司有所回调，未了解到基本面变化，估值调整后将迎来长线布局良机，建议持续关注行业景气度恢复趋势、新产品放量和海外业务进展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251130195629a71ac528&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251130195629a71ac528&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4526","ONC","BK4585"],"gpt_icon":0},{"id":"2585015452","title":"近一個月內，我武生物等多家國內藥企研發項目終止！","url":"https://stock-news.laohu8.com/highlight/detail?id=2585015452","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585015452?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 15:42","pubTimestamp":1763970164,"startTime":"0","endTime":"0","summary":"如近一个月内，多家国内药企的研发项目就已终止。11月14日消息，我武生物公告称，公司管理层决定终止烟曲霉点刺液研发项目，不再开展后续临床试验。该药物用于辅助诊断因烟曲霉致敏引起的I型变态反应性疾病。11月12日，同润生物宣布启动清算解散。11月3日，派格生物发布公告称，已于10月28日申请自愿解散非全资附属公司上海迈迹。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241545319517006f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241545319517006f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","06160","BK4526","BK4139","BK4585"],"gpt_icon":0},{"id":"2585090452","title":"科創生物醫藥ETF漲1.42%，成交額737.09萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585090452","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585090452?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 15:05","pubTimestamp":1763967900,"startTime":"0","endTime":"0","summary":"11月24日，鹏华上证科创板生物医药ETF收盘涨1.42%，成交额737.09万元。该基金成立于2025年3月12日，全称为鹏华上证科创板生物医药交易型开放式指数证券投资基金，管理费率每年0.50%，托管费率每年0.10%，业绩比较基准为上证科创板生物医药指数收益率。规模上，截至11月21日，其最新份额为2.02亿份，规模2.28亿元；流动性方面，截至11月24日，近20个交易日累计成交金额3.08亿元，日均成交金额1542.47万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241513169516f1d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241513169516f1d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","ONC","BK4139","BK4585","06160"],"gpt_icon":0},{"id":"2585071452","title":"本月醫藥企業成機構調研熱門板塊，百濟神州表現尤為突出！","url":"https://stock-news.laohu8.com/highlight/detail?id=2585071452","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585071452?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 13:34","pubTimestamp":1763962497,"startTime":"0","endTime":"0","summary":"2025年，医药企业成为机构调研的热门板块。其中，头部及具备差异化优势的企业已成调研焦点，而研发进展、国际化布局等亦是成为核心话题。在11月，百济神州、盘龙药业、泰恩康等药企都吸引了大批机构目光。其中，百济神州的表现尤为突出。百济神州11月7日，百济神州接受Capital Group等167家机构调研。值得一提的是，百济神州在2025年因其核心产品的强劲表现和研发进展，已吸引了大量机构的关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241339009516cf61&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511241339009516cf61&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","06160","BK4139","BK4585"],"gpt_icon":0},{"id":"2585345202","title":"趨勢研判！2025年中國BTK抑制劑行業發展歷程、產業鏈、市場規模、競爭格局及發展趨勢分析：市場呈現出巨大增長潛力，未來市場競爭愈加激烈[圖]","url":"https://stock-news.laohu8.com/highlight/detail?id=2585345202","media":"智研咨询","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585345202?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 09:12","pubTimestamp":1763946720,"startTime":"0","endTime":"0","summary":"预计2025年全球BTK抑制剂市场规模将达到130亿美元，中国BTK抑制剂市场规模增长至49亿元。目前，我国已批准5种BTK抑制剂用于临床治疗，它们分别为伊布替尼、泽布替尼、阿卡替尼、奥布替尼、匹妥布替尼。随着对BTK抑制剂在疾病发生发展中作用的深入理解和技术的不断进步，我国BTK抑制剂行业正处于快速发展和变革的时期，市场呈现出巨大增长潜力。国内多家药企正在积极研发新一代BTK抑制剂，未来市场竞争将更加激烈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112409155095166537&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112409155095166537&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCR","BK4585","BK4139","ONC","06160","BK4526"],"gpt_icon":0},{"id":"2585520144","title":"創新藥10年冰火淬鍊：千億BD交易背後的繁榮和挑戰（上）丨2025·大覆盤","url":"https://stock-news.laohu8.com/highlight/detail?id=2585520144","media":"钛媒体APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585520144?lang=zh_tw&edition=fundamental","pubTime":"2025-11-24 08:01","pubTimestamp":1763942473,"startTime":"0","endTime":"0","summary":"审批端来看，国家药监局今年打的是“闪电战”，仅上半年就有43个新药获批，同比激增59%，比2024全年只少5个。截至2025年8月，TOP20 MNC已达成22笔引进中国资产的交易，占其全球交易量的近20%；引进中国资产总金额达394亿美元，占全球交易总金额近四成。2017年中国出海的创新药分子均为临床II期，2021年起，临床早期项目占比从20%提至2025年的54%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124080451a4b5b0de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124080451a4b5b0de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02162","BK4585","BK4526","BK4139","06160","BK4022","R","ONC","01801","BK4232"],"gpt_icon":0},{"id":"2585482410","title":"醫藥生物行業跟蹤周報：藥店現金流穩健、估值低，重點推薦益豐藥房、大參林等【東吳醫藥朱國廣團隊】","url":"https://stock-news.laohu8.com/highlight/detail?id=2585482410","media":"国广有话说","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585482410?lang=zh_tw&edition=fundamental","pubTime":"2025-11-23 22:46","pubTimestamp":1763909198,"startTime":"0","endTime":"0","summary":"医药板块表现特点：本周医药板块调整幅度较大。信达生物将于近期向监管机构递交玛仕度肽9mg用于成人体重控制的上市申请。从中药角度，重点推荐佐力药业、方盛制药、东阿阿胶等。估值跌至全年较低水平。新增门店减少，关店数量增多，药房数量于24Q4迎来负增长拐点。益丰药房25Q3销售费用率为25.44%，同比下降1.5pp；销售净利率6.75%，同比提升0.55pp。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123225133a70c6d83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251123225133a70c6d83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1515","BK1574","HK0000165453.HKD","BK1593","ONC","01530","BK1161","02615","06160","BK1583"],"gpt_icon":0},{"id":"2584091616","title":"百濟神州早盤高開逾3% 中信建投維持「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2584091616","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584091616?lang=zh_tw&edition=fundamental","pubTime":"2025-11-18 09:33","pubTimestamp":1763429580,"startTime":"0","endTime":"0","summary":"　　百济神州高开逾3%，截至发稿，涨3.53%，报223.2港元，成交额1196.27万港元。　　11月17日，百济神州宣布III期HERIZON-GEA-01研究取得积极结果。　　中信建投此前指出，百济神州泽布替尼持续放量，上调全年业绩指引。考虑到公司BTK海外放量超预期，以及PD-1在欧盟、日本等其他国家上市放量，以及BCL-2、BTK CDAC、CDK4等重磅管线持续兑现带来商业化进一步兑现，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-11-18/doc-infxusik4211505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ONC","06160","688235"],"gpt_icon":0},{"id":"2584095566","title":"港股異動 | 百濟神州(06160)高開逾3% 百赫安聯合百澤安與化療的3期臨牀研究取得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2584095566","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584095566?lang=zh_tw&edition=fundamental","pubTime":"2025-11-18 09:25","pubTimestamp":1763429130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州高开逾3%，截至发稿，涨3.53%，报223.2港元，成交额1196.27万港元。消息面上，11月17日，百济神州宣布III期HERIZON-GEA-01研究取得积极结果。中信建投此前指出，百济神州泽布替尼持续放量，上调全年业绩指引。考虑到公司BTK海外放量超预期，以及PD-1在欧盟、日本等其他国家上市放量，以及BCL-2、BTK CDAC、CDK4等重磅管线持续兑现带来商业化进一步兑现，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4fc0c44f8d8eb43e289164e52c59bade","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1251922891.USD","LU1719994722.HKD","LU0588546209.SGD","BK4526","LU1303224171.USD","BK1583","BK1161","ONC","BK4585","06160","LU0307460666.USD","LU1969619763.USD","BK1588","LU1770034418.SGD","LU2328871848.SGD","688235","BK1500","BK0239","BK4139"],"gpt_icon":0},{"id":"2583661900","title":"百濟神州授出1.65萬股受限制股份單位激勵員工","url":"https://stock-news.laohu8.com/highlight/detail?id=2583661900","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583661900?lang=zh_tw&edition=fundamental","pubTime":"2025-11-16 18:28","pubTimestamp":1763288885,"startTime":"0","endTime":"0","summary":"11月16日，百济神州（688235/06160/BGNE）发布公告，2025年11月10日，公司董事会薪酬委员会根据2016期权及激励计划的条款，向143名承授人授出涉及共1.65万股美国存托股份的受限制股份单位。这些受限制股份单位相当于21万股股份，约占公司公告之日发行股份总数的0.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511163565527346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU1719994722.HKD","LU1969619763.USD","BK1588","LU1770034418.SGD","ONC","06160","LU1251922891.USD","LU2328871848.SGD","BK4526","BK4139","BK1500","LU1303224171.USD","BK1161","BK4585","LU0588546209.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2583363606","title":"險資四季度掃貨高股息，百濟神州、匯川技術成調研「新寵」","url":"https://stock-news.laohu8.com/highlight/detail?id=2583363606","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583363606?lang=zh_tw&edition=fundamental","pubTime":"2025-11-15 11:14","pubTimestamp":1763176462,"startTime":"0","endTime":"0","summary":"在低利率环境与长期资金属性的双重驱动下，险资正积极优化资产配置结构，一方面加大对高股息股票的配置以抵御利率下行挑战，另一方面则将目光精准投向符合国家战略的新质生产力、高端制造、生物医药等前沿领域，百济神州、汇川技术与立讯精密等公司成为最受追捧的“香饽饽”。在具体的调研标的中，百济神州、汇川技术与立讯精密成为“顶流”，均获得超过20家险资的扎堆调研。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.huanqiu.com/article/4P9Gr01Ia7y","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_huanqiu","symbols":["LU1303224171.USD","BK1583","LU2328871848.SGD","BK4585","ONC","BK1588","BK4139","LU0588546209.SGD","LU0307460666.USD","LU1770034418.SGD","LU1251922891.USD","LU1969619763.USD","BK1500","06160","LU1719994722.HKD","BK1161","BK4526"],"gpt_icon":0},{"id":"2583041715","title":"百濟神州(06160)：授出合共1.65萬股美國存托股份受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2583041715","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583041715?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 22:19","pubTimestamp":1763129941,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年11月10日，董事会薪酬委员会根据2016期权及激励计划的条款授予143名承授人合共1.65万股美国存托股份受限制股份单位。该等受限制股份单位相当于21.4万股股份，约占本公告之日公司发行股份总数的0.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","LU0307460666.USD","LU1303224171.USD","LU1251922891.USD","BK1500","688235","BK4526","LU1770034418.SGD","BK0239","ONC","BK4139","06160","BK4585","LU1719994722.HKD","BK1588","BK1161","LU2328871848.SGD","LU1969619763.USD","BK1583"],"gpt_icon":0},{"id":"2583351341","title":"11月以來機構調研聚焦成長與防禦方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2583351341","media":"大众证券报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583351341?lang=zh_tw&edition=fundamental","pubTime":"2025-11-13 21:51","pubTimestamp":1763041860,"startTime":"0","endTime":"0","summary":"Wind数据显示，11月以来，电子、机械设备、电力设备、医药生物、计算机等行业成为机构投资者调研的核心方向。立讯精密、百济神州关注度较高在11月以来的机构调研中，立讯精密、百济神州、汇川技术等企业成为机构“团宠”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113215346976742f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251113215346976742f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4585","BK4526","06160"],"gpt_icon":0},{"id":"2583593827","title":"信達生物高管錢鐳：百濟神州是窗口期的產物","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593827","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593827?lang=zh_tw&edition=fundamental","pubTime":"2025-11-13 21:15","pubTimestamp":1763039759,"startTime":"0","endTime":"0","summary":"中国创新药企初具全球竞争力，它们有哪些成功经验可供后来者借鉴？百济神州与信达生物先后成立于2010年和2011年，两者都已经有创新药上市，是中国制药产业的代表性企业。但两家企业所走的道路完全不同。百济神州起步就是创新药和全球化，信达生物则先在本土稳扎稳打，然后才谋划国际市场。近日，信达生物首席研发官钱镭在一场论坛上表示，百济神州是特定时期发展起来的企业，其成长路径缺乏可复制性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511133563777018.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511133563777018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","LU2242644610.SGD","LU0588546209.SGD","06160","LU2097828557.USD","BK1161","BK4585","LU0307460666.USD","LU1969619763.USD","BK1583","LU0502904849.HKD","LU1719994722.HKD","BK1589","BK1588","LU1770034418.SGD","BK1500","HK0000165453.HKD","LU1303224171.USD","LU2097828474.EUR","LU0455707207.USD","LU2097828631.EUR","LU2328871848.SGD","ONC","LU2097828805.USD","01801","LU2097828714.EUR","BK4139","BK4526","LU1251922891.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":194,"code":"91000000","status":"200"}]}}